Bristol Myers Squibb Co. closed 5.27% below its 52-week high of $63.33, which the company reached on March 11th.
We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Substack by Magnus Ofstad. In this article, we will ...
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
18h
GlobalData on MSNEC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapyThe EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).
We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...
Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...
Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...
This was the stock's second consecutive day of losses.
Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results